Ainos

AIMD

Market cap $12.9M

2026 Identified as a Key Scale-Up Phase with Expanding Market Verticals and Accelerating Data Flywheel HOUSTON, TX / ACCESS Newswire / April 17, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) today highlighted the continued expansion of its Smell AI deployments, powered by AI Nose, across semiconductor, robotics, and healthcare infrastructure, highlighted by recent third-party research published by VASRO GmbH . The report underscores Smell AI's progression from isolated sensing applications to scalable multi-domain AI perception platform and identifies 2026 as a key scale-up year as Ainos moves toward deployment and repeatable revenue generation.

Expands AI Nose platform from industrial safety into clinical infrastructure HOUSTON, TX / ACCESS Newswire / April 8, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) today announced a partnership with MacKay Memorial Hospital and Topco Scientific Co., Ltd. to deploy its AI Nose technology across high-risk hospital environments.

Report highlights transition to deployment-driven growth, with visible semiconductor rollout and early customer-backed revenue Smell AI, powered by AI Nose, is emerging as a new AI perception layer, supported by accelerating commercialization and expanding industrial adoption HOUSTON, TX / ACCESS Newswire / April 1, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today highlighted findings from a research report published by VASRO GmbH, which points to accelerating commercial progress of "Smell AI" powered by AI Nose, and improving visibility into 2026 deployments. The report notes that Ainos has moved beyond early validation and is now entering a more execution-driven phase, supported by improving financial performance, customer commitments, and a clearer deployment roadmap.

AI Nose drove 499% revenue growth in 2025, with gross margin turning positive to 82.9% 2025 partnerships now driving scaled AI Nose deployments in 2026, supported by disciplined financing HOUSTON, TX / ACCESS Newswire / March 30, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today reported financial results for the year ended December 31, 2025 and outlined commercialization momentum entering 2026. During 2025, Ainos expanded its industrial ecosystem of AI Nose platform across semiconductor, smart factory, robotics, and industrial AI environments, establishing the foundation for deployment-driven growth.

As AI expands beyond vision and language, Ainos advances commercial deployment of AI Nose in industrial environments-positioning the Company at the forefront of this emerging category HOUSTON, TX / ACCESS Newswire / March 19, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform digitizing scent as a native data language for artificial intelligence, today highlighted its inclusion in The Wall Street Journal article " The E-Nose Knows: AI Learns to Smell ," which underscores the emergence of AI capable of sensing and interpreting smell-expanding beyond traditional modalities such as vision, speech, and language. The article describes how AI-powered electronic nose ("E-Nose") systems are being applied across healthcare diagnostics, environmental monitoring, and industrial settings, including semiconductor manufacturing.

AI Nose deployment into front-end wafer fabrication facilities marks a critical validation step in semiconductor manufacturing environments Recurring revenue visibility strengthens as AI Nose deployments scale across the semiconductor ecosystem HOUSTON, TX / ACCESS Newswire / March 12, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for artificial intelligence, today announced that Water Tower Research ("WTR") has published a report highlighting Ainos' accelerating momentum across the semiconductor value chain as its AI Nose platform gains traction in both front-end wafer fabrication and back-end semiconductor manufacturing environments. Key Highlights from the Report: Front-end wafer fab entry unlocks a new frontier for AI Nose validation: Ainos plans to deploy approximately 200 AI Nose systems into front-end wafer fabrication facilities in 1Q26.

Company affirms execution milestones, subscription activation roadmap, and long-term infrastructure vision remain unchanged despite market volatility HOUSTON, TEXAS / ACCESS Newswire / March 9, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced continued validation testing of its AI Nose platform within advanced semiconductor front-end wafer fabrication environments. As part of this qualification phase, Ainos plans to install approximately 200 AI Nose systems across targeted front-end facilities in the first quarter of 2026 for technical validation.

HOUSTON, TEXAS / ACCESS Newswire / March 2, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today issued the following letter from Chairman, President and Chief Executive Officer Eddy Tsai to shareholders, outlining the recurring revenue opportunity under the phased deployment framework of up to 20,000 AI Nose systems, and ongoing validation within advanced front-end semiconductor fabrication environments. To Our Shareholders, I'm proud to share that the AI Nose platform is transitioning from validation-stage pilots into structured industrial deployment.

HOUSTON, TEXAS / ACCESS Newswire / February 23, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced the activation of a phased industrial deployment roadmap under a strategic framework that contemplates the installation of up to 20,000 AI Nose units within semiconductor manufacturing environments. Phased Expansion Framework within Back-end Semiconductor Environments The framework under a Memorandum of Understanding with ASE Technology Holding Co., Ltd.

Open-Label Study Demonstrates Durable Reduction in Oral Inflammation with Favorable Tolerability Profile at Interim Analysis HOUSTON, TEXAS / ACCESS Newswire / February 17, 2026 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a SmellTech platform company digitizing scent as a native data language for artificial intelligence, today announced interim results from its ongoing open-label, multi-dose clinical trial evaluating VELDONA, a low-dose oral interferon alpha formulation, for the treatment of Feline Chronic Gingivostomatitis (FCGS), a severe, chronic inflammatory oral disease in companion animals. The study is designed to enroll 12 client-owned cats diagnosed with FCGS across two dosing cohorts (6,000 IU and 12,000 IU administered orally three times per week for six weeks).